RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Treatment Based on BRCA1 and RAP80 Does Not Extend PFS
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 6
SP 22
OP 23
DO 10.1177/155989771306018
UL http://mdc.sagepub.com/content/13/6/22.2.abstract
AB Patients that received customized lung cancer treatment based on their levels of BRCA1 and RAP80 did not experience an improvement in progression-free survival or overall survival (OS), compared with standard cisplatin plus docetaxel. This article presents data from the Multicenter, Predictive, Prospective, Phase 3, Open, Randomized Pharmacogenomic Study in Patients With Advanced Lung Carcinoma study [BREC; NCT00617656; Moran T et al. J Clin Oncol 2013 (suppl; abstr LBA8002)].